Peizhi Ma

ORCID: 0009-0007-8708-724X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Atrial Fibrillation Management and Outcomes
  • Cardiac Arrhythmias and Treatments
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Venous Thromboembolism Diagnosis and Management
  • Poisoning and overdose treatments
  • Signaling Pathways in Disease
  • Cardiac electrophysiology and arrhythmias
  • Pharmacovigilance and Adverse Drug Reactions
  • Respiratory Support and Mechanisms
  • Apelin-related biomedical research
  • Vitamin K Research Studies
  • Health Systems, Economic Evaluations, Quality of Life
  • Neurological Disorders and Treatments
  • S100 Proteins and Annexins
  • Sepsis Diagnosis and Treatment
  • Potassium and Related Disorders
  • Pancreatic function and diabetes

Henan Provincial People's Hospital
2019-2024

Henan University
2020-2024

Zhengzhou University
2020-2024

Zhengzhou People's Hospital
2019

Duke Medical Center
2016

Clinical Research Institute
2016

Kitasato University
1997

: Neutrophil elastase has been identified as a potential therapeutic target for acute lung injury or respiratory distress syndrome, and Sivelestat is selective, reversible competitive neutrophil inhibitor. This study was designed to investigate the safety, tolerability, pharmacokinetics inhibitory effects of in healthy Chinese subjects. A randomized, double-blind, placebo-controlled single- multiple-dose escalation clinical trial carried out. Briefly, volunteers twelve cohorts with 8 per...

10.1016/j.ejps.2024.106723 article EN cc-by-nc-nd European Journal of Pharmaceutical Sciences 2024-02-07

Atrial fibrillation (AF) is an arrhythmia that prevalent globally, and its incidence grows exponentially with aging. Non-vitamin K antagonist oral anticoagulants (NOACs) have been developed in recent years, it challenges the supremacy of warfarin for thromboembolism prophylaxis AF. Nevertheless, there are limited data specifically evaluating real-life use NOACs elderly patients AF China.This a national, multicenter, non-interventional, cross-sectional study enrolls aged 75 years above from...

10.3389/fcvm.2022.951695 article EN cc-by Frontiers in Cardiovascular Medicine 2022-08-24

Patients with non-valvular atrial fibrillation (NVAF) exhibit a high risk of stroke, which is associated mortality. Thus, stroke prevention crucial for the overall management NVAF. Two categories drugs, vitamin K antagonist warfarin and non-vitamin oral anticoagulants (NOACs), are clinically used to prevent NVAF-related stroke. In some circumstances, NOACs superior warfarin. However, selection NVAF patients affected by many factors, including individual patient characteristics,...

10.3389/fphar.2020.01293 article EN cc-by Frontiers in Pharmacology 2020-08-20

Combined antithrombotic regimens for atrial fibrillation (AF) patients with coronary artery disease, particularly those who have acute syndrome (ACS) and/or are undergoing percutaneous intervention (PCI), presents a great challenge in the real-world clinical scenario. Conventionally, triple therapy (TAT), which consists of combined oral anticoagulant to prevent systemic embolism or stroke along dual antiplatelet arterial thrombosis (CAT), is used. However, TAT has been associated...

10.3389/fcvm.2021.660986 article EN cc-by Frontiers in Cardiovascular Medicine 2021-06-28

As the direct oral anticoagulant most recently approved in China, data pertaining to clinical edoxaban use are still scarce. This study investigated prevalence of and contemporary trends prescription among Chinese patients as well factors associated with its inappropriate a multicentre registry treated real-world practice.

10.1111/bcp.15961 article EN British Journal of Clinical Pharmacology 2023-11-11

To investigate the risk factors of recurrence acute ischemic stroke (AIS) within 1 year and establish a nomogram model for predicting risk.

10.12122/j.issn.1673-4254.2024.12.13 article EN PubMed 2024-12-20

Aim: As the non-vitamin K antagonist oral anticoagulant (NOAC) most recently approved in China, data pertaining to clinical edoxaban use are still scarce. This study investigated prevalence of and contemporary trends prescription among Chinese patients as well factors associated with its inappropriate a multi-center registry treated real-world practice. Methods: real-world, prospective, multicenter, non-interventional included 1005 inpatients edoxaban. According National Medical Products...

10.22541/au.169159868.80558791/v1 preprint EN Authorea (Authorea) 2023-08-09

Background: Acute kidney injury (AKI) is a severe disease. Drug-induced AKI (D-AKI) one type of AKI, which difficult to be diagnosed. The incidence D-AKI in China has rarely been studied. This study aims explore the disease burden, related drugs and diagnosis status D-AKI. Methods: A nationwide cross-sectional survey was conducted adult patients from 23 academic hospitals 17 provinces mainland China. Suspected screened based on serum creatinine changes according 2012 Kidney Disease:...

10.2139/ssrn.3487850 article EN SSRN Electronic Journal 2019-01-01
Coming Soon ...